PARADIGM BIOPHARMACEUTICALS LIMITED

ASX RELEASE

8th December 2020

PARADIGM BIOPHARMACEUTICALS TO HOST INAUGURAL R&D DAY

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is pleased to announce it will be hosting its first R&D Day presentation for investors. As reported during the recent Annual General Meeting, Paradigm is pursuing a global registration for Zilosul® in osteoarthritis. The presentation will cover Paradigm's proposed clinical program, safety and an update on other indications in the company's R&D pipeline. Paradigm's R&D presentation will provide a detailed explanation of the clinical trial program required to achieve successful global registration for OA which is based on feedback received from the Scientific Advice meeting with the EMA in September and the Type-C meeting with the US FDA which is anticipated mid December 2020. Paradigm will advise the market as soon as it receives and reviews the FDA Type C meeting feedback. Incorporating feedback from the agencies aims to ensure there are few or no unexpected setbacks upon successful completion of the Phase 3 clinical program. The Chief Medical Officer will present an update on the clinical study plan, patient enrolment and the projected timeline for clinical readout/s as well as target dates for regulatory submissions. Current and potential investors will be able to participate online via https://web.lumiagm.com on your smartphone, tablet or computer.

Meeting Details:

Event: Paradigm Biopharmaceuticals (PAR) R&D Presentation

Time: AUS: Monday 21st December, 11:00am (AEDT)

US: Sunday 20th December, 7:00pm (Eastern)

Meeting ID: 319-570-478

Agenda

Topic	Presenter
Meeting Welcome	Paul Rennie
Introduction	Jeannie Joughin
OA Clinical Program Update; Trial Outputs and Milestones	Donna Skerrett
Safety and MPS Update	Michael Imperiale
R&D Pipeline	Ravi Krishnan
Revenue Timeline & Summary	Jeannie Joughin
Q&A	Panel
Meeting Closed	

Details of how to 'virtually' attend the Paradigm R&D Day will be available on the Paradigm website, located under the "Presentation" tab prior to the meeting.

Type-C Meeting Feedback

As previously reported, Paradigm submitted the briefing pack to the US FDA on the 23rd of October for a Type C meeting. Paradigm's goal has been to gather and consolidate feedback from the US FDA, EMA, and TGA to have a pivotal protocol acceptable to all major jurisdictions and streamline the approval process in multiple key markets.

The company believes if a clear path to registration is established, with the US FDA and EMA's input, prior to opening the IND and commencement of the Phase 3 clinical program, this will avoid a clinical trial design that does not adequately meet the requirements for registration.

Paradigm looks forward to detailing the feedback from the Type-C meeting to investors once the written response has been received.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulphate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition.

Authorised for release by Paul Rennie, CEO & Interim Executive Chairman.

To learn more about Paradigm Biopharmaceuticals please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com